News
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would refile following data from this Phase III trial.
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
As a new variant that causes 'razor blade throat' spreads, the FDA updates vaccine warnings to include information on heart ...
The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback